<DOC>
	<DOCNO>NCT01896869</DOCNO>
	<brief_summary>This study enroll patient metastatic pancreatic cancer stable disease FOLFIRINOX chemotherapy . The main purpose study compare survival patient receive ipilimumab pancreatic tumor vaccine patient continue receive FOLFIRINOX . Funding Source - FDA OOPD</brief_summary>
	<brief_title>A Phase 2 , Multicenter Study FOLFIRINOX Followed Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine Treatment Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria ( abbreviate ) : 1 . Documented adenocarcinoma pancreas 2 . Stable metastatic pancreatic cancer 812 dos FOLFIRINOX 3 . ECOG performance status 0 1 4 . Life expectancy great 3 month 5 . Adequate organ marrow function define studyspecified laboratory test . 6 . Must use acceptable form birth control study 7 . Oxygen saturation room air &gt; 92 % Exclusion Criteria ( abbreviate ) : 1 . Surgery within 4 week dose investigational agent ( exception minor procedure ) 2 . Off FOLFIRINOX treatment 70 day prior treatment study 3 . Prior chemotherapy metastatic pancreatic cancer ( FOLFIRINOX adjuvant therapy ) . 4 . History prior treatment ipilimumab , antiPD1 antibody , CD137 agonist , antiCD40 antibody 5 . Received nononcology live vaccine therapy one month prior dose ipilimumab/vaccine 6 . Receiving investigational agent 7 . Any following concomitant therapy : IL2 , interferon , immunosuppressive agent , chronic use systemic corticosteroid 8 . History symptomatic autoimmune disease immune impairment . Thyroid disease allow . 9 . Known brain metastasis 10 . Radiographic ascites apparent physical exam require intervention 2 month prior enrollment 11 . Uncontrolled intercurrent illness 12 . Known suspected hypersensitivity GMCSF 13 . Chronic HIV , Hepatitis B Hepatitis C 14 . Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>CTLA-4</keyword>
	<keyword>antibody</keyword>
	<keyword>FOLFIRINOX</keyword>
</DOC>